1584. In Vitro Activity of Imipenem/Relebactam against Gram-Negative Pathogens from Patients with Bloodstream Infections in the United States and Canada – SMART 2018

BACKGROUND: Relebactam (REL) inhibits class A and C β-lactamases, including KPC, and was approved in the United States combined with imipenem (IMI) and cilastatin for complicated urinary tract and intraabdominal infections. We evaluated the activity of IMI/REL against non-Morganellaceae (NME) and P....

Descripción completa

Detalles Bibliográficos
Autores principales: Lob, Sibylle, Hackel, Meredith, Young, Katherine, Motyl, Mary, Sahm, Daniel F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777755/
http://dx.doi.org/10.1093/ofid/ofaa439.1764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777755/
http://dx.doi.org/10.1093/ofid/ofaa439.1764

Ejemplares similares